SCHEMBL12499645

SCHEMBL12499645

CC/C(=C\c1ccc(Cl)nc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 2/20 0.50
NAPRT Q6XQN6 1/20 0.43
RAB9A P51151 3/20 0.40
GRIK1 P39086 1/20 0.40
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 2/20 0.40
EPHX2 P34913 1/20 0.38
PPARG P37231 1/20 0.38
DGAT1 O75907 1/20 0.37
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
NFE2L2 Q16236 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12499649 1.00 TBXAS1 (0.50) TBXAS1NAPRTRAB9AGRIK1NPC1
SCHEMBL1914012 0.81 TBXAS1 (0.47) TBXAS1RAB9AGRIK1NPC1EPHX2
SCHEMBL1914097 0.81 TBXAS1 (0.50) TBXAS1GRIK1EPHX2PPARGMAPT
SCHEMBL5173409 0.80 TBXAS1 (0.58) TBXAS1GRIK1ALDH1A1EPHX2PPARG
SCHEMBL15758231 0.80 AKR1C3 (0.52) TBXAS1NAPRTRAB9ANPC1HTT
SCHEMBL15758230 0.80 AKR1C3 (0.52) TBXAS1NAPRTRAB9ANPC1HTT
SCHEMBL11335306 0.80 GRIK1 (0.59) TBXAS1GRIK1HTTALDH1A1EPHX2
SCHEMBL321287 0.80 GRIK1 (0.59) TBXAS1GRIK1HTTALDH1A1EPHX2
Hydrochloric Acid SCHEMBL27356431 0.78 GRIK1 (0.58) TBXAS1GRIK1HTTALDH1A1EPHX2
SCHEMBL1707590 0.77 TBXAS1 (0.38) TBXAS1NAPRTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9765054-B2 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2017-09-19 US disclosed
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation (US) 2014-06-12 US disclosed
EP-2667709-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2013-12-04 EP disclosed
WO-2012103008-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. (US) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF HDAC1, HDAC7, HDAC5 TBXAS1 3168/4885NAPRT 690/4885RAB9A 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.